Objectives. To analyse the association of autoantibodies against cardiolipin (CL) and oxidized low density lipoproteins wcopper-oxidized low density lipoprotein (oxLDL), malondialdehydemodified LDL (MDA-LDL)x with rheumatoid arthritis (RA) and cardiovascular complications.
Rheumatoid arthritis (RA) is a chronic inflammatory disease with a wide variety of disease manifestations. In many patients, the outcome of RA is complicated by cardiovascular diseases and this is the main cause of the increased mortality in this disorder w1, 2x. Autoantibodies against cardiolipin (CL) w3-6x and oxidatively modified low density lipoproteins wcopperoxidized LDL (oxLDL)x w5, 7x, including malondialdehydemodified LDL (MDA-LDL) w8x, have been suggested to have a predictive value for cardiovascular diseases. These antibodies have been shown to partially recognize the same epitopes, and might thus represent overlapping specificities w9x. RA is also characterized by the presence of rheumatoid factors (RF) w10x and, in some patients, of antinuclear antibodies (ANA). However, the relationship between different types of autoantibodies and especially their relation to RA and cardiovascular disease, is unclear.
Autoantibodies against cardiolipin (aCL) have been associated with several other autoimmune diseases, like antiphospholipid syndrome (APS) w11x and systemic lupus erythematosus (SLE) w12x. aCL are considered risk factors for arterial and venous thrombotic events w13x, cerebral infarction w14, 15x, thrombocytopenia w16x and recurrent abortion w17x.
A correlation between oxidative processes of lipids and atherosclerosis or myocardial infarction (MI) w3, 5, 18x has been supported by experiments in which endothelial cells, monocytesumacrophages and smooth muscle cells were incubated with LDL w19, 20x, leading to the formation of oxLDL. The pathogenic function of oxLDL was proven in animal models and Ylä -Herttuala et al. w21, 22x showed that atherosclerotic lesions of rabbit and man contained oxLDL. Several groups have now reported that autoantibodies against oxLDL are elevated in different cardiovascular diseases w5, 8, 23-26x. One possible pathogenicuatherogenic role of these autoantibodies could be increased formation of immune complexes by oxLDL and autoantibodies, leading to an acceleration of the formation of foam cells w27x.
As a byproduct of the lipid peroxidation, malondialdehyde (MDA) is formed. This compound can bind to lysine residues of proteins and build up covalent links to proteins. Increased levels of autoantibodies against MDA-LDL are present in sera of patients with SLE, scleroderma and severe inflammatory vasculitis, e.g. periarteritis nodosa w28x.
The aim of this study was to analyse the three isotypes of autoantibodies against CL, oxLDL and MDA-LDL in RA and to evaluate their relation to cardiovascular complications.
Methods

Study groups
One hundred and twenty-one patients with rheumatoid arthritis (RA) w29x, 33 men and 88 women, from northern Sweden were consecutively included at the Department of Rheumatology during 4 months of the study. All patients except nine had RF (according to Waaler-Rose), with titres ranging between 1u40 and 1u40 000. ANA were present in 37 of 116 tested patients. The demographic and clinical data at time of inclusion are summarized in Table 1 . The accumulated inflammatory activity of the disease was estimated as described w30x. Cardiovascular anduor cerebrovascular events, defined as MI (n=12), strokeutransient ischaemic attacks (n=8) and deep vein thrombosisupulmonary embolism (n=3) (as defined in Wå llberg-Jonsson et al. w2x) occurred in 18 patients after the onset of RA. Fiftyfive patients were current or ex-smokers. One hundred and six patients were or had been treated with diseasemodifying anti-rheumatic drugs (DMARDs) including sulphasalazine, antimalarials, intramuscular or oral gold, penicillamine, methotrexate, cyclosporin, azathioprine, chlorambucil and cyclophosphamide (06 months with each drug).
As a control group, we used referents that were part of an extensive nested case-referent study (MONICA) organized in the same region, described in detail in published references w31, 32x. The mean age ("S.D.) of the referents at sampling was 55.0"7.6 yr and there were 142 men and 84 women.
This study was approved by the Research Ethics Committee of Umeå University.
Isolation and oxidative modifications of LDL Serum lipoproteins were isolated by preparative ultracentrifugation w33x. Oxidative modifications of LDL were done by CuSO 4 and malonaldehyde bisdimethylacetal w27, 34x.
Determination of antibodies against CL, oxLDL and MDA-LDL Autoantibodies against CL, oxLDL and MDA-LDL were determined by ELISA as previously described w5, 27x with minor modifications. To obtain the highest possible specificity of the assay, the serum dilution for determination of IgG antibodies against CL was 1u100, for IgM antibodies 1u50 and for IgA antibodies 1u30. For assay of autoantibodies against oxLDL and MDA-LDL, plates were coated with antigens using 5 mguml, while serum dilutions for assay of all isotypes were 1u20. All samples were analysed at the same time, using the same batch of antigen. The intra-assay variation for antibodies against CL was 8-12%, for antibodies against MDA-LDL 8-11% and for antibodies against oxLDL 13%. The inter-assay variation for determination of all Levels of autoantibodies in subgroups of patients with a cardiovascular or cerebrovascular event, such as MI, strokeutransient ischaemic attacks and deep vein thrombosisupulmonary embolism, as well as patients with hypertension, were compared with the levels in the rest of the patient group. There were no differences in the levels of autoantibodies against CL, oxLDL or MDA-LDL between patients with these complications and those without. The patients with MI had a significantly higher prevalence of IgG antibodies against MDA-LDL (P=0.04) compared with patients without MI. There were significant relations between certain of these autoantibody species. Correlations between IgG, IgM and IgA antibodies against oxLDL and MDA-LDL were present (r=0.38, P<0.0001; r=0.71, P<0.0001; r=0.54, P<0.0001, respectively). There were also significant correlations between IgM and IgA antibodies against oxLDL and CL (r=0.59, P<0.0001; r=0.31, P=0.0005, respectively). Also, IgG, IgM and IgA antibodies against MDA-LDL and CL showed strong relations (r=0.34, P=0.0001; r=0.69, P<0.0001; r=0.31, P=0.0004, respectively). There were no relations between the levels of RF and antibodies against aCL, oxLDL or MDA-LDL and no correlation between these autoantibodies and accumulated 
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Discussion
Patients with RA had increased levels and prevalence of all three isotypes of aCL autoantibodies compared with healthy controls. Moreover, patients with extraarticular disease had increased IgM and IgA antibodies against CL compared with RA patients without these manifestations. The high mortality of RA patients has been the subject of several investigations w1x. Epidemiological investigations of autoimmune diseases have linked inflammation to cardiovascular events w2x. Cellular and humoral components of the immune system are involved in the pathogenesis of both RA and atherosclerosis. The significance of autoantibodies in RA has not been settled as of yet. Autoantibodies in serum of RA patients include RF and ANA, but also antiphospholipid antibodies, like aCL. aCL antibodies have been suggested to be predictive markers for MI w3, 5x and for arterial and venous thrombosis w13, 35x. A recent prospective study, which included hyperlipidaemic patients, showed that aCL antibodies are independent risk factors for atherosclerotic vascular diseases w6x. aCL antibodies occur in both RA and SLE. The antibodies are commonly present in SLE w35x, while reports in patients with RA are inconsistent w36-38x. Jacobs et al. w36x reported that aCL antibodies, especially of IgM class, were present in RA patients, but there was no association of these autoantibodies to clinical or laboratory measurements of disease activity. In another study, autoantibodies against CL were present in 16% of RA and SLE patients w37x. There was no association of aCL to clinical manifestations. Vittecoqet et al. w38x registered low concentrations of aCL antibodies in only 7% of patients with mild RA and there was no relationship to RF or clinical manifestations.
The prevalence of aCL antibodies in our study is thus higher than previously reported. Our control material is well defined and represents a true population-based selection. We have used the same control material in two earlier studies on autoantibodies as predictive factors for stroke w31, 32x. In these studies, the numbers of women and men in the patient and control groups were the same and there were only marginal differences in the prevalence and concentration of antibodies against CL between persons who developed stroke and those who remained healthy. Regarding antibodies against oxidatively modified LDL, there were no differences at all between those who remained healthy and those who developed stroke. Thus, the high prevalence and concentration of autoantibodies in RA found in this study should not depend on the selection of the control The numbers of individuals with levels of autoantibodies over the cut-off values are presented in brackets.
material and therefore should represent a true difference. The population from the northern part of Sweden is genetically different from the rest of the Swedish population, and this might also be of importance for the high prevalence and levels of autoantibodies found in our study.
There are few reports about the presence of autoantibodies to oxidatively modified LDL in RA patients w39x. Studies have shown oxLDL present in the synovium of RA patients w40, 41x and its involvement in joint destruction. Autoantibodies against oxLDL are present in cardiovascular diseases, and increased levels have been related to carotid atherosclerosis w42x, peripheral vascular diseases w43x and MI w5, 7x. There was an association of IgG antibodies against MDA-LDL in patients with MI. Our earlier studies have shown a strong predictive effect of these antibodies for future MI w5x. The higher prevalence of IgM antibodies against MDA-LDL in patients treated with corticosteroids might indicate a more severe disease with an ongoing immune response. These reports are the first of their kind, showing that these antibodies might be related to disease activity and to cardiovascular complications. There were substantial correlations between the concentration of antibodies against CL and against oxidatively modified LDL. This phenomenon could be caused by common epitopes present on the different autoantigens w9x, or by cross-reactions to the antibody level w44x. Thus, at the moment it is not clear which of these antibody species has the most important effects on the vessel wall.
Rheumatoid nodules are constituted of a ring of macrophages, surrounding necrotic tissue. These formations are initiated and chronically activated by extravascular immune complexes. Receptor FcgRIIIa expressed on macrophages binds immune complexes, which leads to secretion of TNFa and an inflammatory response w45x. High levels of autoantibodies might lead to formation of circulating immune complexes and activation of complements. In particular, antibodies against CL seem to have a rather strong tendency to immune complex formation w46, 47x. The effect of immune complexes on the vascular endothelium is activation of endothelial cells and upregulation of their adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) w48x. These molecules function as anchors for monocytesumacrophages and T cells. Infiltration of monocytesumacrophages and T cells in the vessel wall might be considered as the common event for both atherosclerosis and the inflammatory reaction initiated by immune complexes. This inflammation further leads to damage of surrounding bone tissue by the action of metalloproteinases, which are induced by the pro-inflammatory cytokines IL-1b, TNFa and IL-6. Rajavashisth et al. w49x showed that pro-inflammatory cytokines anduor oxLDL increase endothelial cell expression of membrane type 1-metalloproteinase (MT1-MMP). Thus, there are many similarities in the pathogenesis of inflammatory vessel disease and atherosclerosis.
To summarize, we found increased levels and prevalence of autoantibodies against CL, oxLDL and MDA-LDL in RA patients, and also associations with the severe form of RA and with cardiovascular complications. To analyse these antibodies in RA might possibly be used to predict the severity of disease as well as cardiovascular complications. The functional correlations between the autoantibodies and disease remain to be elucidated.
